ESGIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESGIC (ESGIC).
Esgic contains butalbital (a barbiturate that enhances GABA-A receptor activity, producing sedation), acetaminophen (inhibits cyclooxygenase, particularly COX-2, in the CNS, reducing pain and fever), and caffeine (antagonizes adenosine receptors, providing vasoconstriction and adjuvant analgesic effect).
| Metabolism | Butalbital: hepatic via cytochrome P450 (CYP2C9, CYP2C19); Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; also metabolized by CYP2E1 to toxic NAPQI; Caffeine: hepatic via CYP1A2. |
| Excretion | Renal: butalbital 60-70% unchanged, acetaminophen ~4% unchanged, caffeine ~1% unchanged. Biliary/fecal: minimal. |
| Half-life | Butalbital: ~35 hours; acetaminophen: ~2-3 hours; caffeine: ~3-6 hours. Clinical context: butalbital's long half-life leads to accumulation with repeated dosing, requiring cautious use. |
| Protein binding | Butalbital: ~45% bound to plasma proteins; acetaminophen: 10-25% bound; caffeine: 25-36% bound, primarily to albumin. |
| Volume of Distribution | Butalbital: 0.8 L/kg; acetaminophen: 0.9 L/kg; caffeine: 0.5 L/kg. Large Vd indicates extensive tissue distribution. |
| Bioavailability | Oral: 90-100% for butalbital and acetaminophen; caffeine ~100%. |
| Onset of Action | Oral: 30-60 minutes for analgesic effect. |
| Duration of Action | 4-6 hours for analgesic effect; butalbital's sedative effects may persist longer due to long half-life. |
1-2 capsules (50 mg butalbital, 325 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not to exceed 6 capsules per day.
| Dosage form | TABLET |
| Renal impairment | For CrCl <30 mL/min: avoid use or extend dosing interval to every 12 hours; not to exceed 4 doses per day. For dialysis: dose after hemodialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce daily dose by 50% and monitor. Child-Pugh C: contraindicated. |
| Pediatric use | Children <12 years: not recommended. For ≥12 years, weight <50 kg: 1 capsule (50 mg butalbital, 325 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, max 4 per day. |
| Geriatric use | Start with 1 capsule every 6 hours; monitor for sedation, confusion, and hepatotoxicity; reduce total daily dose if frail or low body weight. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESGIC (ESGIC).
| Breastfeeding | Acetaminophen and caffeine are excreted in breast milk with M/P ratios of approximately 0.91 and 0.52 respectively; butalbital has limited data but likely excreted. Caution advised due to potential infant sedation with butalbital. Avoid if possible. |
| Teratogenic Risk | First trimester: Butalbital (barbiturate) is associated with increased risk of oral clefts and neural tube defects; acetaminophen and caffeine are generally considered low risk. Second and third trimesters: Butalbital may cause neonatal withdrawal syndrome and coagulopathy due to vitamin K deficiency; acetaminophen is safe at therapeutic doses; caffeine may be associated with reduced fetal growth at high intake. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component; porphyria; severe hepatic impairment; patients with acute intermittent porphyria; patients with known intolerance to barbiturates, acetaminophen, or caffeine; concurrent use of other barbiturates or CNS depressants (relative); breastfeeding; history of substance abuse.
| Precautions | Hepatotoxicity from acetaminophen (avoid exceeding 4 g/day; risk with alcohol use); butalbital dependence and withdrawal; CNS depression; impaired ability to drive or operate machinery; risk of medication-overuse headache; severe skin reactions (Stevens-Johnson syndrome) with acetaminophen; respiratory depression with high doses or in elderly/debilitated patients. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, liver function, and signs of butalbital dependence. Fetal monitoring for growth restriction (caffeine effect) and neonatal withdrawal signs at delivery. |
| Fertility Effects | No significant known effects on fertility from acetaminophen or caffeine at therapeutic doses. Butalbital may cause hormonal imbalances affecting ovulation. |